Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -0.01%93 3-Year ROIIC % is 11.99 as of Mar. 2026, which is 12% above its 10-year median of 10.73. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹603.80 (Fairly Valued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 59.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Metropolis Healthcare's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 11.99%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Metropolis Healthcare's 3-Year ROIIC % or its related term are showing as below:
NSE:METROPOLIS's 3-Year ROIIC % is ranked better than 59.11% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.82
vs NSE:METROPOLIS: 11.99
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Metropolis Healthcare 3-Year ROIIC % Related Terms
Metropolis Healthcare 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, NTRA: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Metropolis Healthcare (NSE:METROPOLIS) has a 3-Year ROIIC % of 11.99 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Metropolis Healthcare and its competitors. This is 12% above median its historical median of 10.73. According to the industry distribution chart, Metropolis Healthcare ranks #83 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 40.9%.
Is Metropolis Healthcare's 3-Year ROIIC % too high?
Metropolis Healthcare's current 3-Year ROIIC % of 11.99 is 12% above median its 10-year median of 10.73. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.82. Metropolis Healthcare's value of 11.99 is 1362.2% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #83 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #83 out of 203 companies for 3-Year ROIIC %. This puts Metropolis Healthcare in the upper half of its industry. The industry median 3-Year ROIIC % is 0.82. Metropolis Healthcare's value of 11.99 is 1362.2% above this benchmark. While the company's 10-year median is 10.73 vs. the industry median of 0.82, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.82, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current 3-Year ROIIC % of 11.99 is 1362.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current 3-Year ROIIC % is 11.99, which is 12% above median its own 10-year median of 10.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹603.80, compared to a current price of ₹582.20 — trading 3.6% below its estimated fair value. The current 3-Year ROIIC % is 11.99, which is 12% above median its 10-year median of 10.73 and 1362.2% above the Medical Diagnostics & Research industry median of 0.82. Metropolis Healthcare's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current 3-Year ROIIC % is 11.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹582.20 is trading 3.6% below its estimated GF Value™ of ₹603.80.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
3-Year ROIIC %: 11.99 (12% above median its 10-year median of 10.73)
GF Value™: ₹603.80 vs. price of ₹582.20 (3.6% below fair value)
Industry Position: 1362.2% above the Medical Diagnostics & Research median (#83 of 203)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
